Jason MBA - Caribou Biosciences Chief Officer

CRBU Stock

USD 1.34 0.06 4.29%

Insider

Jason MBA is Chief Officer of Caribou Biosciences

Age	56
Phone	510 982 6030
Web	https://cariboubio.com

Caribou Biosciences Management Efficiency

The company has return on total asset (ROA) of (0.2514) % which means that it has lost $0.2514 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.436) %, meaning that it created substantial loss on money invested by shareholders. Caribou Biosciences' management efficiency ratios could be used to measure how well Caribou Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Caribou Biosciences to Peers

Predict price of Caribou Biosciences

Caribou Biosciences currently holds 27.11 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Caribou Biosciences has a current ratio of 11.99, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Caribou Biosciences' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	MS MBA	Fate Therapeutics	N/A
	David Liu	Beam Therapeutics	N/A
	Edward III	Fate Therapeutics	48
	Andrew May	Intellia Therapeutics	N/A
	Alexis Komor	Beam Therapeutics	N/A
	Mark Shearman	Editas Medicine	64
	Andrew MD	Verve Therapeutics	45
	Rodger MD	Crispr Therapeutics AG	57
	George Church	Editas Medicine	71
	Nitin Sood	Adaptive Biotechnologies Corp	N/A
	Harry III	Editas Medicine	63
	Mark Adams	Adaptive Biotechnologies Corp	57
	Shaun Foy	Crispr Therapeutics AG	N/A
	David Liu	Prime Medicine, Common	N/A
	Emmanuelle Charpentier	Crispr Therapeutics AG	N/A
	Ann Lee	Prime Medicine, Common	63
	Tycho Peterson	Adaptive Biotechnologies Corp	50
	Lawrence Klein	Crispr Therapeutics AG	42
	David Liu	Editas Medicine	N/A
	Margaret Beaudoin	Verve Therapeutics	55
	Craig Mello	Crispr Therapeutics AG	N/A

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. The company was incorporated in 2011 and is headquartered in Berkeley, California. Caribou Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. Caribou Biosciences (CRBU) is traded on NASDAQ Exchange in USA. It is located in 2929 7th Street, Berkeley, CA, United States, 94710 and employs 158 people. Caribou Biosciences is listed under Biotechnology category by Fama And French industry classification.

Management Performance

	Return On Equity	-0.44
	Return On Asset	-0.25

Caribou Biosciences Leadership Team

Elected by the shareholders, the Caribou Biosciences' board of directors comprises two types of representatives: Caribou Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Caribou. The board's role is to monitor Caribou Biosciences' management team and ensure that shareholders' interests are well served. Caribou Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Caribou Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.

	Sriram MBA, Chief Officer
	Amy CFA, Vice Communications
	Cindy Hayashi, VP HR
	Ryan Fischesser, Interim Controller
	Jason MBA, Chief Officer
	JD Esq, Chief Secretary
	Timothy MBA, Chief Officer
	Reigin Zawadzki, Chief Officer
	Syed MD, Chief Officer
	Rachel Haurwitz, CEO, CoFounder
	Steven Kanner, Chief Officer
	Ruhi MBA, Chief Officer
	Justin Skoble, VP Operations
	Daniel Poon, Vice Technology

Caribou Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Caribou Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-0.44
	Return On Asset	-0.25
	Operating Margin	(16.67) %
	Current Valuation	(74.76 M)
	Shares Outstanding	90.55 M
	Shares Owned By Insiders	10.03 %
	Shares Owned By Institutions	62.12 %
	Number Of Shares Shorted	10.8 M
	Price To Book	0.45 X
	Price To Sales	11.05 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Caribou Stock Analysis

When running Caribou Biosciences' price analysis, check to measure Caribou Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Caribou Biosciences is operating at the current time. Most of Caribou Biosciences' value examination focuses on studying past and present price action to predict the probability of Caribou Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Caribou Biosciences' price. Additionally, you may evaluate how the addition of Caribou Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC